Skip to main content

Beyfortus Disease Interactions

There is 1 disease interaction with Beyfortus (nirsevimab).

Moderate

Nirsevimab (applies to Beyfortus) Bleeding disorder

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Bleeding Associated with Coagulation Defect

Nirsevimab should be given with caution to infants and children with clinically significant bleeding disorders such as thrombocytopenia or any coagulation disorder.

References

  1. (2023) "Product Information. Beyfortus (cvx 307) (nirsevimab (cvx 307))." sanofi pasteur
  2. (2023) "Product Information. Beyfortus (cvx 306) (nirsevimab (cvx 306))." sanofi pasteur

Beyfortus drug interactions

There are 3 drug interactions with Beyfortus (nirsevimab).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer